Member Info for Harrogate4

IFA 90 "Does that equate to £200 ex-China?"

Maybe, his buy out estimate seems high to me, but who knows?

Have been in email contact with a friend of mine, a Professor at UAMS ( University of Arkansas for Medical Science).

His view on Trump?

Dangerous and unhinged (my phrase --can't repeat what he actually said)

He was mostly worried, as are many academics in the States apparently) that Trump will cut numerous research grants.

On Avacta, he was well aware, and estimated what he called a realistic buy out price at successful Phase 1b Stage completion at between 20 and 25 Billion dollars ( from an American Big Pharma) given the Pipeline potential and the size of the market.

For interest thought I would pass this on (for what it's worth of course).

Touk " but if you don’t write they certainly won’t read it"

True, and well done to D-Geeman for writing to them.

I was just bemoaning the seemingly low standards now prevailing regarding those we write to, in not replying.

D-Geeman " Maybe they will read it."

Best of luck with that.

In the past weeks I have written ( for various reasons all connected to Avacta and all in a helpful way) to several people, in all cases with zero response.

As I have said before, lack of response seems to be the modern way of dealing with enquiries.

It used to be called rudeness.

Got it now thanks.

Bella ------Isn't it Renee at Thrust or am I getting mixed up ( quite possible). There's a Carly at the other lot Carly Scaduto.

The list of treatable indications is growing and the buyout cost is increasing, but CC knows that.

The stage when the data is overwhelmingly compelling .will soon be here in a few months.

Lower production costs

Am wondering if Nvidia's $593 billion loss in a day may be an exemplar of what may happen now when companies invest in ADCs rather than PDCs given the lower production, simpler manufacturing and all the other significant advantages of the latter.

The case of Astrazeneca, Daiichi Sanko and Enhertu springs to mind.

Yesterday I used the mymsk@mskcc.org general email address to send an email with the 16th January RNS attached with a plea for it to be passed on to the direct email of Dr Virgilio Sacchini ( in view of his Avacta enthusiasm) as recently revealed in that interview he gave.

Annoyingly, the MSK Website gives you all information you might need except the direct email contact addresses of the Doctors.

Correction 16th January RNS

D-Geeman, Bella

Thanks for your very interesting input on this.

Noted from Carly Scaduto's website ( just below My Story and My Work), that she offers the opportunity to "Let's Start a Conversation".

So anyone so inclined could ask her how things are going etc and maybe open up the conversation by sending her the weblink for the 16th December RNS just in case she hasn't seen it. She has something on her site that allows you to do this or the alternative would be just to email her at Carly@carlyscadutoconsulting.com.

Presumably from CC's Irish surname, she may have some connection with the Emerald Isle somewhere along the line, so thought it may be a good idea to contact the IACR (Irish Association for Cancer Research) in Dublin and also the "Breakthrough Cancer Research" organization in Cork to similarly give them some detail about Avacta's recent progress in case they are interested. I will do this over the weekend.

D-Geeman

"So she is going to be liaising with US media, by and large."

I would have thought almost exclusively with US media.

The appointment of Carly Scaduto of Carly Scaduto Consulting to deal with Media Contact is first mentioned in the CFO appointment RNS of 13th January.

Her experience comprises 20 plus years in Corporate Comms, handling the Press, TV etc, taking photographs to professional standards and strategic marketing.

Why would this appointment be made unless CC thought that such experience would soon be needed?

To me, it confirms that she (CC) is highly confident that the Tech that Avacta has to offer, will soon be in high demand, and she is simply lining up someone to deal with the inevitable interest.

D-Geeman ----- "Can anyone who's had helpful replies from the company in the past suggest the best address to give him?"

That's a real poser with this company where secrecy is an artform. My own experience is that all contact with them is subcontracted as it were, to others, and the others usually do not reply to you. To be charitable, it may just be the modern way of dealing with things, it used to be called rudeness.

The person seeking to make contact may be best placed to take a scattergun approach and copy in everybody who may be able to answer their enquiry and on that basis the following may be useful, even if only one of them responds.

avacta@icrhealthcare.com ( taking care to mention any or all of Mary Jane Elliot/Jessica Hodgson/ Max Bennett

avacta@consilium-comms.com ( supposed to deal with investor enquiries but may be helpful)

renee@thrustsc.com (Renee Leck at Thrust Strategic Communications, newly appointed Stateside by Avacta.

A low grade alternative method of securing attention would be just to phone up and ask for whoever you are hoping to speak to and say you are from the Winners section at Lytham St Ann (Premium Bonds) and need to speak to them urgently. It very often works.

Great idea.

Excellent

Here are the contact details for Salivary Gland Cancer UK:

Address: International House, 36-38 Cornhill, City of London, London EC3V 3NG, United Kingdom.

Phone: 020 7272 2716

Email: emma.kinloch@salivaryglandcancer.uk

Website: www.salivaryglandcancer.uk

D-Geeman ----"I would hope they are talking to AVCT"

So would I, but the odds are that they are completely unaware of either Avacta or the progress the company are making towards treating SGC.

That's what happens when it's all kept so under the radar.

No, why don't you have a go.